title: Eruptive squamous cell carcinomas after vemurafenib therapy.
abstract: BACKGROUND
  Vemurafenib is an oral BRAF inhibitor recently approved for the treatment of metastatic melanoma. Patients treated with this medication have been reported to have the occurrence of squamous cell carcinoma (SCC) and/or actinic keratosis (AK).
  
  
  OBJECTIVE
  We report the case of a patient treated with vemurafenib for papillary thyroid carcinoma who subsequently developed multiple SCCs and AK of the skin. The lesions were deemed related to the medication and treated with excision. In addition, subsequent development of SCCs and AK was successfully prevented with a combination of isotretinoin and 5-fluorouracil in this patient. We discuss postulated mechanisms for these findings, as well as potential preventive therapy with the aforementioned combination regimen in patients undergoing treatment with vemurafenib.
authors.forename: Rana
authors.initials: R
authors.lastname: Mays
authors.forename: Jonathan
authors.initials: J
authors.lastname: Curry
authors.forename: Kevin
authors.initials: K
authors.lastname: Kim
authors.forename: Kenneth
authors.initials: K
authors.lastname: Tsai
authors.forename: Anita
authors.initials: A
authors.lastname: Arora
authors.forename: Farhan
authors.initials: F
authors.lastname: Khan
authors.forename: Marigdalia
authors.initials: M
authors.lastname: Ramirez-Fort
authors.forename: Ana
authors.initials: A
authors.lastname: Ciurea
mesh_terms: D001706:Biopsy; D002291:Carcinoma, Papillary / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology; D003937:Diagnosis, Differential; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib